Dr Karen Mullen FFPM joined Boyds in 2022 as Chief Medical Officer (CMO) and Vice President of Clinical and Medical Affairs.

A highly skilled pharmaceutical physician with more than 20 years’ experience in medical affairs and drug research and development, Karen has worked in Europe, the USA and Australia across a wide range of pharmaceutical therapy areas, including vaccines, cell and gene therapies and oncology.

Karen is the Chief Medical Officer and leads our Clinical and Medical Affairs department and its team of pharmaceutical physicians, providing medical monitoring support, and safety, pharmacovigilance, scientific and medical advice across a wide range of client projects including advanced therapies, orphan drugs and oncology.

She joined Boyds from GlaxoSmithKline, where she was Country Medical Director for the UK and Ireland and responsible for leading and managing a large medical department across clinical research, pharma, and vaccines. Her previous roles at GSK include Head of Medical Affairs, Director of Vaccines, and Director of Metabolic Medicine.

Karen is a Fellow of Faculty of Pharmaceutical Medicine (FFPM) and was a member of the Prescription Medicines Code of Practice Authority (PMCPA) Appeal Board for three years. Previously, she also chaired the Association of the British Pharmaceutical Industry (ABPI) Code of Practice Working Group on behalf of the Faculty of Pharmaceutical Medicine (FPM) as well as being involved in various other ABPI working groups.


Chief Medical Officer and Vice President, Clinical and Medical Affairs

T +44 (0)1270 270010
E karen.mullen@boydconsultants.com